Screener
AbCellera Biologics Inc. ABCL Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:18 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001703057-26-000028
| Line item | Three months ended March 31, 2025 | Three months ended March 31, 2026 |
|---|---|---|
| Proceeds from marketable securities | 190,027 | 143,802 |
| Receipt of grant funding | 1,018 | 1,361 |
| Long-term investments and other assets | (7,484) | (105) |
| Net cash provided by (used in) investing activities | 7,935 | (25,081) |
| Cash flows from financing activities: | ||
| Proceeds from long-term liabilities and other | 5,970 | 7,192 |
| Net cash provided by financing activities | 5,970 | 7,192 |
| Effect of exchange rate changes on cash and cash equivalents | 590 | (38) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is AbCellera Biologics Inc.'s investing cash flow?
- AbCellera Biologics Inc. (ABCL) reported investing cash flow of -$25.08M in Q1 2026.
- How has AbCellera Biologics Inc.'s investing cash flow changed year-over-year?
- AbCellera Biologics Inc.'s investing cash flow decreased by 416.1% year-over-year, from $7.94M to -$25.08M.
- What is the long-term trend for AbCellera Biologics Inc.'s investing cash flow?
- Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s investing cash flow has grown at a -28.3% compound annual growth rate (CAGR), from -$332.25M to $87.75M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about AbCellera Biologics Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude